Aaref Hilaly - Guardant Health Independent Director
| GH Stock | USD 16.67 0.28 1.71% |
Director
Mr. Aaref A. Hilaly is Independent Director of the Company. Mr. Hilaly has served as a member of our board of directors since April 2015. Mr. Hilaly joined Sequoia Capital, a VC firm, in April 2012 and has served as a Managing Member of Sequoia Capital Operations, LLC since January 2015. He currently serves on the board of directors of MobileIron, Inc. and a number of privatelyheld companies, including Clari, Inc. and ThousandEyes, Inc. Prior to joining Sequoia Capital, Mr. Hilaly served as Vice President, Engineering at Symantec Corporationration from June 2011 to April 2012. He was the Chief Executive Officer of Clearwell Systems, Inc., a provider of analytics software for electronic discovery, from April 2005 until Clearwell Systems, Inc.s acquisition by Symantec Corporationration in June 2011. Prior to that, Mr. Hilaly was the founder and Chief Executive Officer of CenterRun, Inc., a pioneer in datacenter automation, which was acquired by Sun Microsystems, Inc since 2015.
| Age | 46 |
| Tenure | 9 years |
| Professional Marks | MBA |
| Address | 3100 Hanover Street, Palo Alto, CA, United States, 94304 |
| Phone | 855 698 8887 |
| Web | https://guardanthealth.com |
Guardant Health Management Efficiency
The company has Return on Asset (ROA) of (0.1764) % which means that for every 100 dollars spent on asset, it generated a loss of $0.1764. This is way below average. Likewise, it shows a return on total equity (ROE) of (4.3813) %, which implies that it produced no returns to current stockholders. Guardant Health's management efficiency ratios could be used to measure how well Guardant Health manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.28. The current Return On Capital Employed is estimated to decrease to -0.37. As of now, Guardant Health's Debt To Assets are increasing as compared to previous years. The Guardant Health's current Fixed Asset Turnover is estimated to increase to 2.51, while Total Assets are projected to decrease to under 1.4 B.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Daniel Weiner | Simulations Plus | 66 | |
| Bridget Duffy | Evolent Health | 60 | |
| Frank Gordon | HealthStream | 55 | |
| Allen Moseley | Streamline Health Solutions | 46 | |
| David Ralph | Simulations Plus | 68 | |
| Thompson Dent | HealthStream | 68 | |
| Linda Rebrovick | HealthStream | 62 | |
| Robert Musslewhite | Evolent Health | 44 | |
| Judith Starkey | Streamline Health Solutions | 69 | |
| Cheryl Scott | Evolent Health | 70 | |
| Diane Holder | Evolent Health | 70 | |
| Matthew Hobart | Evolent Health | 47 | |
| Bruce Felt | Evolent Health | 61 | |
| Michael Kirshbaum | Evolent Health | 39 | |
| Lisa LaVange | Simulations Plus | N/A | |
| Wyche Green | Streamline Health Solutions | 45 | |
| Kenan Lucas | Streamline Health Solutions | 33 | |
| Thaddeus Grasela | Simulations Plus | 61 | |
| Martiny Harris | HealthStream | 59 | |
| Michael Kaplan | Streamline Health Solutions | 50 | |
| Michael DAmato | Evolent Health | 66 | |
Management Performance
| Return On Equity | -4.38 | ||||
| Return On Asset | -0.18 |
Guardant Health Leadership Team
Elected by the shareholders, the Guardant Health's board of directors comprises two types of representatives: Guardant Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Guardant. The board's role is to monitor Guardant Health's management team and ensure that shareholders' interests are well served. Guardant Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Guardant Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| AmirAli Talasaz, President COO, Director | ||
| Richard Lanman, Chief Medical Officer | ||
| Marcel Roche, Vice President - Finance | ||
| Ian Clark, Lead Independent Director | ||
| Leena DasYoung, General Manager,Chief LUNAR Officer | ||
| John Saia, Chief Secretary | ||
| DEREK BERTOCCI, CFO | ||
| Terilyn Monroe, Chief Officer | ||
| Craig MD, Chief Officer | ||
| Andy Ament, VP Operations | ||
| Kumud Kalia, Chief Officer | ||
| Michael Bell, Chief Officer | ||
| Michael Wiley, Chief Legal Officer | ||
| Aaref Hilaly, Independent Director | ||
| Darl Moreland, Senior Quality | ||
| Jennifer Higgins, Vice Affairs | ||
| Dipchand Nishar, Independent Director | ||
| Christopher Freeman, Chief Officer | ||
| Helmy Eltoukhy, CoCEO CoFounder | ||
| Mark Jacobstein, Chief User Engagement Officer | ||
| Bahija Jallal, Director | ||
| Stanley Meresman, Independent Director | ||
| Lynn Lewis, IR Contact Officer | ||
| Darya Chudova, VP Technology | ||
| Samir Kaul, Independent Director |
Guardant Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Guardant Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -4.38 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | (0.85) % | ||||
| Operating Margin | (0.73) % | ||||
| Current Valuation | 2.21 B | ||||
| Shares Outstanding | 121.71 M | ||||
| Shares Owned By Insiders | 4.10 % | ||||
| Shares Owned By Institutions | 93.77 % | ||||
| Number Of Shares Shorted | 7.64 M | ||||
| Price To Earning | (12.01) X |
Guardant Health Investors Sentiment
The influence of Guardant Health's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Guardant. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Guardant Health's public news can be used to forecast risks associated with an investment in Guardant. The trend in average sentiment can be used to explain how an investor holding Guardant can time the market purely based on public headlines and social activities around Guardant Health. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Guardant Health's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Guardant Health's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Guardant Health's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Guardant Health.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Guardant Health in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Guardant Health's short interest history, or implied volatility extrapolated from Guardant Health options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Guardant Health. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. For more detail on how to invest in Guardant Stock please use our How to Invest in Guardant Health guide.Note that the Guardant Health information on this page should be used as a complementary analysis to other Guardant Health's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for Guardant Stock analysis
When running Guardant Health's price analysis, check to measure Guardant Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Guardant Health is operating at the current time. Most of Guardant Health's value examination focuses on studying past and present price action to predict the probability of Guardant Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Guardant Health's price. Additionally, you may evaluate how the addition of Guardant Health to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |
Is Guardant Health's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Guardant Health. If investors know Guardant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Guardant Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.28) | Revenue Per Share 5.036 | Quarterly Revenue Growth 0.222 | Return On Assets (0.18) | Return On Equity (4.38) |
The market value of Guardant Health is measured differently than its book value, which is the value of Guardant that is recorded on the company's balance sheet. Investors also form their own opinion of Guardant Health's value that differs from its market value or its book value, called intrinsic value, which is Guardant Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Guardant Health's market value can be influenced by many factors that don't directly affect Guardant Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Guardant Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Guardant Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Guardant Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.